Elizabeth Masson-Hurlburt
Corporate Officer/Principal at CORMEDIX INC.
Net worth: 192 483 $ as of 2024-03-30
Profile
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CORMEDIX INC.
0.08% | 2024-01-11 | 45,397 ( 0.08% ) | 192 483 $ | 2024-03-30 |
Elizabeth Masson-Hurlburt active positions
| Companies | Position | Start |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Former positions of Elizabeth Masson-Hurlburt
| Companies | Position | End |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2018-02-28 |
Training of Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Private companies | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
- Stock Market
- Insiders
- Elizabeth Masson-Hurlburt
